SRL Diagnostics announces technology to diagnose Hypertension in pregnancy
New Delhi, June 4 (IBNS):: SRL Diagnostics, a global diagnostics chain, introduced a breakthrough medical test to diagnose hypertensive disorders in pregnancy recently at its state of the art lab New Delhi.
Priced at Rs. 2850, SRL launched the first of its kind biomarker, PLGF (Placental Growth Factor) to meet the alarming threat of the expecting mothers in recent times.
PLGF (Placental Growth Factor) is used for accurate diagnosis and prognosis of “pre-eclampsia”, a major cause of maternal, foetal, neonatal morbidity and mortality.
The new test will help gynaecologists to diagnose pre-eclampsia early and in planning delivery and decision making for timely hospital transfer.
Most cases of pre-eclampsia develop in healthy women bearing their first child. Pre-eclampsia can happen as early as 20 weeks of gestation and can only be resolved by delivery of the baby. However, late diagnosis of the condition can lead to long term maternal complications that can be fatal to the mother and the child both.
As per the industry findings, it is postulated that the incidence of pre-eclampsia is around 10-12% amongst Indian women irrespective of zones, against an incidence of 5-8% in developed countries. Pre-eclampsia accounts for around 70% of all cases of hypertension in pregnancy and its sequelae eclampsia account for for 24% of all maternal deaths in India.
Talking at launch of the test, Dr. B R Das, President - Research and Innovation,Mentor - Molecular Pathology and Clinical Research Service, SRL Diagnostics said that, “Pre-eclampsia (PE) a syndrome characterised by hypertension and protien in urine, is suspected in around 10-12% of pregnancies in India. Although the exact cause of this disorder is not known, it is widely accepted that placenta is the source of this condition, and it can also affect the mother's kidney, liver, and brain. Earlier, there was no single test to diagnose or predict the outcome of pre-eclampsia. SRL Diagnostics is the first Indian lab to introduce PlGF. The marker begins to decrease 11 to 9 weeks before the onset of pre-eclampsia, and falling substantialy during the 5 weeks before the onset of hypertension or proteinuria.”
It is also known that Pre-eclampsia sometimes develop without any symptoms. High blood pressure might develop slowly, but more commonly it has a sudden onset. Pregnancies complicated by hypertension including pre-eclampsia are associated with increased risk of adverse fetal, neonatal and maternal health.
Other signs and symptoms of preeclampsia might include severe headaches, changes in vision, upper abdominal pain, nausea decreased urine output, decreased levels of platelets in your blood, impaired liver function and shortness of breath.
There are a number of risk factors for pre-eclampsia, including first pregnancy, advanced maternal age (over 35 years) and carrying multiple fetuses. Other risk factors, such as a history of high blood pressure, can be minimized through diet and exercise.Those over 40, under 20, or who have certain health conditions including diabetes also have greater risks.
“Hypertension in pregnancy may lead to various complications when it is unregistered. Especially when it is due to Pre-eclampsia, maternal and fetal morbidity and mortality can be reduced by early recognition and institutional management. Apart from routine antenatal check ups, women should undergo early screening processes to identify placental dysfunction, and, if pre-eclampsia is suspected, it may be prudent to start appropriate management as soon as possible. PlGF is going to help clinicinas in deciding that," added Dr. B R Das.
Jammu and Kashmir: Govt sets up health club at Panchayat level to check COVID-19 spread Wed, Sep 23 2020
Himachal records 130 COVID-19 cases, two deaths Wed, Sep 23 2020
Residents of J&K benefit as Kashmir gets its first NAT-PCR facility Wed, Sep 23 2020
Baby elephant rescued by villagers near Guwahati Wed, Sep 23 2020
COVID-19: India registers 1085 new deaths Wed, Sep 23 2020
Zimbabwe to open traditional Chinese medicine clinic Wed, Sep 23 2020
Beijing reports no new COVID-19 cases Wed, Sep 23 2020
Around 2,500 volunteers have received 1st component of Russian COVID-19 vaccine : Gamaleya Tue, Sep 22 2020